Notably, the multi-target tyrosine kinase inhibitor AL3818 (anlotinib), targeting also FGFR1/2/3 (33), is in phase III trial for metastatic/advanced alveolar soft part sarcoma, leiomyosarcoma and synovial sarcoma (NCT03016819). This evidence concerns the gene FGFR1 and alveolar soft part sarcoma.